News Conatus axes staff after latest failure of Novartis-partnered NASH drug Phil Taylor Conatus, liver disease, NASH, Novartis 0 Comment Conatus has said it will have to cut around 40% of its workforce and jettison some pipeline projects Share X Conatus axes staff after latest failure of Novartis-partnered NASH drug https://pharmaphorum.com/news/conatus-axes-staff-after-latest-nash-trial-failure/
News/ R&D Novartis takes option on NASH drug from Conatus Richard Staines Conatus, Gilead, Intercept, Novartis, Shire 0 Comment Swiss pharma takes option on FXR agonist emricasan. Share X Novartis takes option on NASH drug from Conatus https://pharmaphorum.com/news/novartis-takes-option-nash/
